Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2019-07-26 | Diane L. Parks, MBA has been a director since July 8, 2019. After the Annual Meeting, the Nominating Committee will be comprised of Dr. Zeldis (Chair), Mr. Lapointe and Ms. Parks. Ms. Parks joined the Board of Directors on July 8, 2019, and therefore did not receive any compensation during the fiscal year ended December 31, 2018. |
| 2020-08-07 | Diane L. Parks, MBA has been a director since July 2019. ... Our Board of Directors has an Audit Committee, which is comprised of Mr. Lapointe (Chair), Ms. Parks and Dr. Rubin. ... Our Board of Directors has a Nominating and Corporate Governance Committee ("Nominating Committee"), which is comprised of Dr. Zeldis (Chair), Mr. Lapointe and Ms. Parks. |
| 2021-08-10 | Diane L. Parks, MBA has been a director since July 2019. ... Our Board of Directors has an Audit Committee, which is comprised of Mr. Lapointe (Chair), Ms. Parks and Dr. Rubin. ... Our Board of Directors has a Nominating and Corporate Governance Committee ("Nominating Committee"), which is comprised of Dr. Zeldis (Chair), Mr. Lapointe and Ms. Parks. ... Compensation of Directors table shows Diane L. Parks earned $45,625 in cash and $30,000 in option awards for a total of $75,625 in 2020. |
| 2022-08-05 | Diane L. Parks, MBA has been a director since July 2019. From February 2016 until July 2018, she served as Head of U.S. Commercial and Senior Vice President of Marketing, Sales & Market Research at Kite Pharma, Inc., a biopharma company developing cancer immunotherapy products with a primary focus on genetically engineered autologous T cell therapy with chimeric antigen receptors. From October 2014 to October 2015, Ms. Parks served as Vice President of Global Marketing at Pharmacyclics LLC, a biopharmaceutical company primarily focused on the development of cancer therapies. Prior to Pharmacyclics LLC, Ms. Parks held senior leadership roles as Vice President of Sales for Amgen, Inc., a biopharmaceutical company, representing oncology and nephrology products, and Senior Vice President of Specialty Biotherapeutics and Managed Care at Genentech, Inc., a biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions that was acquired by Roche Holding AG in 2009. At Genentech, she led the launches of multiple products as well as commercial development of Lucentis® and Rituxan®. She also currently serves on the Board of Directors of Calliditas Therapeutics AB (publ), TriSalus Life Sciences, Kura Oncology, Inc., CTI BioPharma Corp., Celularity Inc. and the Lymphoma Research Foundation. During the last five years, she served on the board of managers of Healogix LLC. Ms. Parks holds a BS from Kansas State University and an MBA in marketing from Georgia State University. She has been a commercial leader in the biotech and pharma industry for over 30 years. |
| 2023-08-07 | Ms. Parks holds a BS from Kansas State University and an MBA in marketing from Georgia State University. |
| 2024-04-29 | Diane L. Parks, MBA has been a director since July 2019. From February 2016 until July 2018, she served as Head of U.S. Commercial and Senior Vice President of Marketing, Sales & Market Research at Kite Pharma, Inc. The Audit Committee includes Ms. Parks. The Compensation Committee includes Ms. Parks. |
Data sourced from SEC filings. Last updated: 2025-12-07